Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Post by lonc17on Sep 29, 2005 10:57pm
546 Views
Post# 9633911

proof of efficacy?

proof of efficacy?So the trial begins at last… I thought this might bump the stock 10 cents when I first read the news release. Why the spike? Well, when you think about it, the fact they are enrolling this trial could be taken as proof of efficacy at Marsden. Brad has said they wouldn’t want to market the product as a five-day treatment if one day works fine. The Marsden trial was set up to maximize the dosage (volume and days) to overcome the immune response seen in other trials. They would have been stupid to start with the one-day trial. It would also be unwise to run the one-day trial (cost) unless they were already seeing positive results from Marsden. Why back up the dosage unless the five-days was showing efficacy? On a different note, is it possible for a true long to take money off the table? Seriously, if you put all the clues together over the past six years, then this appears to be the best and safest cancer treatment to arrive in a very long time… It seems a shame to part with even a few shares.
Bullboard Posts